Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + penpulimab as adjuvant therapy after curative surgery or ablation for high‑risk hepatocellular carcinoma
CTR20230033Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Anlotinib + penpulimab with Placebo (2 arms). Primary endpoint: Recurrence‑free survival (RFS). Started May 2023; status: active.
02
Drugs
anlotinibpenpulimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20230033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230033.